PE20081722A1 - Sal estroncio de atorvastatina y composicion farmaceutica que la incluye - Google Patents

Sal estroncio de atorvastatina y composicion farmaceutica que la incluye

Info

Publication number
PE20081722A1
PE20081722A1 PE2008000205A PE2008000205A PE20081722A1 PE 20081722 A1 PE20081722 A1 PE 20081722A1 PE 2008000205 A PE2008000205 A PE 2008000205A PE 2008000205 A PE2008000205 A PE 2008000205A PE 20081722 A1 PE20081722 A1 PE 20081722A1
Authority
PE
Peru
Prior art keywords
pharmaceutical composition
strontium salt
atorvastatin strontium
atorvastatin
hypercholesterolemia
Prior art date
Application number
PE2008000205A
Other languages
English (en)
Inventor
Eunk Sook Kim
Sun Young Jang
Bo Sung Kwon
Sangmin Yun
Kwee Hyun Suh
Gwan Sun Lee
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of PE20081722A1 publication Critical patent/PE20081722A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

SE SE REFIERE A UNA FORMA CRISTALINA DE SAL DE ESTRONCIO DE ATORVASTATINA CARACTERIZADA PORQUE SI ESPECTRO DE DIFRACCION DE POLVO DE RAYOS X MUESTRA PICOS MAYORES QUE TIENEN VALORES I/I9 DE POR LO MENOS 10% A 2 THETA+-0.2 DE 3.8, 5.2, 6.2, 7.9, 10.7, 19.7 Y 24.0. REFERIDA TAMBIEN A UN PROCEDIMIENTO DE PREPARACION Y UNA COMPOSICION FARMACEUTICA QUE COMPRENDE 1 A 70% POR PESO EN BASE A LA COMPOSICION TOTAL. DICHO COMPUESTO ES UTIL EN LA PREVENCION O TRATAMIENTO DE LA HIPERLIPIDEMIA E HIPERCOLESTEROLEMIA
PE2008000205A 2007-01-29 2008-01-28 Sal estroncio de atorvastatina y composicion farmaceutica que la incluye PE20081722A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020070008896A KR100878140B1 (ko) 2007-01-29 2007-01-29 아토바스타틴의 스트론튬염 또는 이의 수화물, 및 이를포함하는 약학 조성물

Publications (1)

Publication Number Publication Date
PE20081722A1 true PE20081722A1 (es) 2009-01-22

Family

ID=39674220

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000205A PE20081722A1 (es) 2007-01-29 2008-01-28 Sal estroncio de atorvastatina y composicion farmaceutica que la incluye

Country Status (16)

Country Link
US (1) US20100120888A1 (es)
EP (1) EP2121596A4 (es)
JP (1) JP2010516756A (es)
KR (1) KR100878140B1 (es)
CN (1) CN101600688A (es)
AR (1) AR065070A1 (es)
AU (1) AU2008211906B2 (es)
BR (1) BRPI0808369A2 (es)
CA (1) CA2675996A1 (es)
CL (1) CL2008000170A1 (es)
IL (1) IL200069A0 (es)
MX (1) MX2009007922A (es)
NZ (1) NZ579339A (es)
PE (1) PE20081722A1 (es)
TW (1) TW200844093A (es)
WO (1) WO2008093951A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101973922B (zh) * 2009-05-27 2013-01-23 天津和美生物技术有限公司 阿伐他汀半锶盐多晶型物、其制备和作为HMG-CoA酶抑制剂的应用
KR20120011249A (ko) 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
IN2014DN06942A (es) * 2012-01-20 2015-04-10 Lianyungang Jinkang Hexin Pharmaceutical Co Ltd
CN102935076A (zh) * 2012-11-29 2013-02-20 康普药业股份有限公司 一种含阿托伐他汀钠的胶囊及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
SI0848705T1 (en) * 1995-07-17 2002-04-30 Warner-Lambert Company Crystalline r-(r*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- (phenylamino)carbonyl)-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
UA74075C2 (en) 2001-06-29 2005-10-17 Warner Lambert Co NOVEL CRYSTALLINE FORMS [R-(R*,R*)]-2-(4-FLUOROPHENYL)-b, d-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1??-PYRROLE-1-HEPTANOIC ACID CALCIUM SALT (2:1)(ATORVASTATIN) (VARIANTS)
EP1744770A2 (en) * 2004-05-06 2007-01-24 Osteologix A/S High yield and rapid syntheses methods for producing metallo-organic salts
CA2570389A1 (en) * 2004-06-17 2005-12-29 Osteologix A/S Treatments comprising strontium for rheumatic and arthritic diseases and pain

Also Published As

Publication number Publication date
KR20080070951A (ko) 2008-08-01
EP2121596A4 (en) 2010-03-17
IL200069A0 (en) 2010-04-15
TW200844093A (en) 2008-11-16
KR100878140B1 (ko) 2009-01-12
BRPI0808369A2 (pt) 2014-08-19
JP2010516756A (ja) 2010-05-20
CN101600688A (zh) 2009-12-09
US20100120888A1 (en) 2010-05-13
CA2675996A1 (en) 2008-08-07
WO2008093951A1 (en) 2008-08-07
MX2009007922A (es) 2009-08-07
AU2008211906B2 (en) 2010-11-18
AR065070A1 (es) 2009-05-13
AU2008211906A1 (en) 2008-08-07
CL2008000170A1 (es) 2008-05-23
EP2121596A1 (en) 2009-11-25
NZ579339A (en) 2011-03-31

Similar Documents

Publication Publication Date Title
ATE520406T1 (de) Kristalline form des ibandronat-natriums
HK1133787A1 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
SG196789A1 (en) Pharmaceutical preparation having excellent photostability
EA201101398A1 (ru) Замещенные пиперидины в качестве антагонистов ccr3
HK1186127A1 (zh) 通過給予神經生長因子拮抗劑及其組合物來治療骨關節炎疼痛的方法
ATE486872T1 (de) Maleimid-derivate, pharmazeutische zusammensetzungen und verfahren zur behandlung von krebs
RS52823B (en) NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
AR073298A1 (es) Formas cristalinas del 2-tiazolil-4-quinolil-oxi amidas, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento de la infeccion por hcv.
MY150602A (en) Subtituted-quinoxaline-type piperidine compounds and the uses thereof
WO2008089463A3 (en) Substituted 1,3-dioxanes and their uses
CR8647A (es) Forma cristalina delta-d de clorhidrato de ivabradina, su procedimiento de preparacion y composiciones farmacueticas que la contienen
TW200626158A (en) Naphthaline derivatives
TW200621313A (en) Pharmaceutical compositions
PE20081722A1 (es) Sal estroncio de atorvastatina y composicion farmaceutica que la incluye
WO2008062476A3 (en) Pharmaceutical composition comprising rosuvastatin or pharmaceutically accepatble salts thereof
JO2897B1 (en) Organic compounds
EP2137175A4 (en) NOVEL PHENANTHRENNEQUINONE-BASED COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR THE TREATMENT OR PREVENTION OF METABOLIC SYNDROME INVOLVING DISEASES
WO2012024489A3 (en) Compounds and compositions for ossification and methods related thereto
ATE522500T1 (de) Amidderivate als ionenkanalliganden sowie pharmazeutische zusammensetzungen und verwendungsverfahren dafür
DE602006019710D1 (de) Magnesiumsalze von hmg-coa-reduktase-hemmern
GR20050100466A (el) Βελτιωμενες φαρμακευτικες συνθεσεις που περιεχουναναστολεις της αναγωγασης του 3-υδροξυ-3-μεθυλογλουταρυλοσυνενζυμου α (hmg-coa) και μεθοδος παρασκευης αυτων
ATE538105T1 (de) Substituierte tetrazolverbindungen und ihre verwendung
BRPI0815531A2 (pt) "compostos, composição farmacêutica, composição cosmética, uso cosmético de uma composição e uso de um composto"
UA88127C2 (ru) Таблетка для профилактики и лечения заболеваний зубов и пародонта
EA201170182A1 (ru) Композиции эпросартана

Legal Events

Date Code Title Description
FD Application declared void or lapsed